Drug Profile
Research programme: interferon beta - BioRexis
Alternative Names: Longer-acting interferon βLatest Information Update: 14 Mar 2011
Price :
$50
*
At a glance
- Originator BioRexis Pharmaceutical Corporation
- Class Interferons
- Mechanism of Action Interferon beta stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Multiple sclerosis
Most Recent Events
- 31 Dec 2010 Discontinued - Preclinical for Multiple sclerosis in USA (unspecified route)
- 31 Dec 2007 No development reported - Preclinical for Multiple sclerosis in USA (unspecified route)
- 19 Jul 2004 This programme is available for licensing (http://www.biorexis.com)